Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption

Rheumatology

Volumn 46, Issue 9, 2007, Pages 1433-1437

  Amital, Howard ^d   Heilweil Harel, M ^a   Ulmansky, R ^a   Harlev, M ^b   Toubi, E ^c   Hershko, A ^a   Naparstek, Y ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c BNAI ZION MEDICAL CENTER   (Israel)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Anti DNA antibodies; Autoantibodies; Laminin; Lupus nephritis; SLE

Indexed keywords

AUTOANTIBODY; CYCLOPHOSPHAMIDE; DNA ANTIBODY; EPITOPE; LAMININ; PROTEIN ANTIBODY; SEPHAROSE; UNCLASSIFIED DRUG; VRT101 ANTIBODY; VRT101 PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY ISOLATION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ACTIVITY; HUMAN; IMMUNOADSORBENT; MAJOR CLINICAL STUDY; NONHUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN ISOLATION; RATING SCALE; RHEUMATIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; DNA; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HUMANS; LAMININ; LUPUS ERYTHEMATOSUS, SYSTEMIC; PEPTIDE FRAGMENTS; PLASMAPHERESIS; SEVERITY OF ILLNESS INDEX; SHEEP;

EID: 34548266213     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem181     Document Type: Article

References (30)

1. Wade Y, Ito S, Ueno M, Nakano M, Arakawa M, Gejyo F. Renal outcome and predictors of clinical renal involvement in patients with silent lupus nephritis. Niphron Clin Pract 2004;98:c105-11.
2. Sasaki T, Muryoi T, Hatakeyama A et al. Circulating anti-DNA immune complexes in active lupus nephritis. Am J Med 1991;91:355-62.
3. Naparstek Y, Ben-Yehuda A, Madaio MP et al. Binding of anti-DNA antibodies and inhibition of glomerulonephritis in MRL-lpr/lpr mice by heparin. Arthritis Rheum 1990;33:1554-9.
4. Ehrenstein MR, Katz DR, Griffiths MH et al. Human IgG anti-DNA antibodies deposit in kidneys and induce protelnuris in SCID mice. Kidney Int 1995;48:705-11.
5. Hylkema MN, van Bruggen MC, tTen HT et al. Histone-containing Immune complexes are to a large extent responsible for anti-dsDNA reactivity in the Farr assay of active SLE patients. J Autoimmun 2000;14:159-68.
6. Deocharan B, Qing X, Lichauko J, Putterman C. Alpha-actinin is a cross-reactive renal target for pathogenic anti-DNA antibodies. J Immunol 2002;168:3072-8.
7. Zhao Z, Weinstein E, Tuzova M et al. Cross-reactivity of human lupus anti-DNA antibodies with alpha-actinin and nephritogenic potential. Arthritis Rheum 2005;52:522-30.
8. Migliorini P, Pratesi F, Bongiomi F, Moscato S, Scovuzzo M, Bombardieri S. The targets of nephritogenic antibodies in systemic autoimmune disorders. Autoimmun Rev 2002;1:168-73.
9. Amital H, Heilwell M, Ulmansky R et al. Treatment with a laminin-derived peptide suppresses lupus nephritis. J Immunol 2005;175:5516-23.
10. Ben-Yehuda A, Rasooly L, Bar-Tana R et al. The urine of SLE patients contains antibodies that bind to the laminin component of the extracellular matrix. J Autoimmun 1995;8:279-91.
11. Schuger L, Skubitz AP, Gilbride K, Mandel R, He L. Laminin and heparan sulfate proteoglycan mediate epithelial cell polarization in organotypic cultures of embryonic lung cells: Evidence implicating involvement of the inner globular region of laminin beta 1 chain and the hoparan sulfate groups of heparan sulfate proteoglycan. Dev Biol 1996;179:264-73.
12. Horvath L, Brownson NE, Fields GB, Skubitz AP. Laminin peptides stimulate human noutrophil motility. J Immunol 1994;152:5447-56.
13. Skubitz AP, Letoumeau PC, Wayner E, Furcht LT. Synthetic peptides from the carboxy-terminal globular domain of the A chain of laminin: Their ability to promote call adhesion and neurits outgrowth, and interact with heparin and the beta 1 integrin subunit. J Cell Biol 1991;115:1137-48.
14. Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatal 2002;29:288-91.
15. Ehrenstein M, Loghurst C, Isenberg DA. Production and analysis of IgG monoclonal and-DNA antibodies from systemic lupus erythematosus (SLE) patients. Clin Exp Immunol 1993;92:39-45.
16. Winkler TH, Jahn S, Kalden JR. IgG human monoclonal anti-DNA autoantibodies from patients with systemic lupus erythematosus. Clin Exp Immunol 1991;85:379-85.
17. Kalsi JK, Martin AC, Himbayashi Y et al. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol Immunol 1996;33:471-83.
18. Ginsberg B, Keiser H. A Millipore filter assay for antibodies to naive DNA in sera of patients with systemic lupus erythematosus. Arthritis Rheum 1973;16:199-207.
19. Christensen SR, Keshgarian M, Alexopoulou L, Flavell RA, Akira S, Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 2005;202:321-31.
20. Andre-Schwartz J, Datta SK, Shoonfeld Y, Isenberg DA, Stollar BD, Schwartz RS. Binding of cytoskeletal proteins by monoclonal anti-DNA lupus autoantibodies 1. Clin Immunol Immunopathol 1984;31:261-71.
21. Mason LJ, Ravirajan CT, Rahman A, Putterman C, Isenberg DA. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum 2004;50:866:70.
22. Kikkawa Y, Virtanen I, Miner JH. Mesangial cells organize the glomerular capillaries by adhering to the G domain of laminin alpha5 in the glomerular basement membrane. J Cell Biol 2003;161:187-96.
23. Kootstra CJ, Bergijk EC, Veninga A et al. Qualitative alterations in laminin expression in experimental lupus nephritis. Am J Pathol 1995;147:476-88.
24. Hershko AY, Naparstek Y. Removal of pathogenic autoantibodies by immunoadsorption. Ann NY Acad Sci 2005;1051:635-46.
25. Takamori M, Moruta T. Immunoadsorption in myasthenia gravis based on specific ligands mimicking the immunogenic sites of the acetylcholine receptor. Ther Apher 2001;5:340-50.
26. Muller J, Wallukat G, Dandell M et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-91.
27. Furie RA, Cash JM, Cronin ME et al. Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65.
28. Jones DS, Barstad PA, Feild MJ et al. Immunospecific reduction of antioligonucleotide antibody-forming cells with a tetrakis-oligonucleotide conjugate (LJP 394), a theropeutic candidate for the treatment of lupus nephritis. J Med Chem 1995;38:2138-44.
29. Weisman MH, Bluestein HG, Berner CM, de Haan HA. Reduction in circulating dsDNA antibody titer after administration of LJP 394. J Rheumatol 1997;24:314-8.
30. Linnik MD, Hu JZ, Heilbrunn KR, Strand V. Hurley FL, Joh T. Relationship between antibodies-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:1129-37.